Switching Back to Mounjaro from Wegovy: What You Need to Decide

Why people switch back: the clinical picture

Most people who moved from Mounjaro to Wegovy did so for one of a handful of reasons: cost, availability, or a prescriber's recommendation. Some found Wegovy's side-effect profile easier to manage; others were drawn by the lower price point, a gap that became significant after Eli Lilly's list-price increase in September 2025, which pushed Mounjaro's higher doses to around £330 per four-week pen on some private prescriptions. If the reasons you left Mounjaro no longer apply (supply has stabilised, your budget has changed, or you are not achieving the weight loss you hoped for on semaglutide) switching back becomes a reasonable clinical conversation.

The trial evidence is relevant here. In SURMOUNT-5, a 72-week head-to-head study comparing tirzepatide with semaglutide 2.4mg in adults with obesity, tirzepatide produced greater average weight reduction, a finding that informed NICE's appraisal of tirzepatide (TA1026). Wegovy's newer 7.2mg dose, approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026, narrows that gap, so if you are already on semaglutide and responding well, the picture is less clear-cut than the headline figures suggest. The question is not which medicine wins on a spreadsheet; it is which medicine suits you, at this point in your treatment. You can read more about how the two medicines compare mechanically on our semaglutide vs tirzepatide mechanism page.

Switching is not inherently better or worse than staying. A prescriber needs to weigh your current weight loss, your side-effect history, any health changes since you were last on Mounjaro, and the dose you were on when you stopped.

What the switch actually involves, dose, timing and the clinical review

Tirzepatide and semaglutide are not interchangeable milligram for milligram. Mounjaro starts at 2.5mg, a dose chosen to let your system adjust before titration begins. If you were previously on a higher Mounjaro dose, a prescriber will decide whether you restart at 2.5mg or at a different point, based on how long you have been off it and how your body tolerated it before. There is no standard answer; the SmPC guidance and clinical judgement both feed into that decision.

Timing matters too. There is a washout period to consider between stopping one GLP-1 medicine and starting another. Your prescriber will advise on the interval, it is not something to manage by reading forums. If you are thinking about this switch, our page on whether switching back to Mounjaro from Wegovy is clinically appropriate goes into the eligibility questions in more detail, and our page on what switching from Mounjaro to Wegovy involves covers the outbound direction if that context helps.

For patients transferring from another provider, nume verifies current treatment and dose before any prescription is issued. That is true whether you are coming from Wegovy or any other regimen. Evidence of your current treatment is part of the consultation, not a formality.

One practical note: when your Mounjaro pen arrives, it comes by DPD the next working day in a plain box with nothing on the outside to indicate what is inside. The KwikPen itself stays refrigerated at 2–8°C, as the patient information leaflet sets out. Worth factoring in if your circumstances have changed since you last stored it.

Mounjaro vs Wegovy side by side: the key facts

Both medicines are licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity. Both carry the Black Triangle (▼) designation, meaning the MHRA collects additional safety data. Both are prescription-only. The differences that tend to drive switches are outlined below.

The Wegovy vs Mounjaro comparison covers the evidence in more depth, including what the SURMOUNT-5 head-to-head data actually showed and how to read trial figures in context. Our page on the cost difference between the two medicines explains how that gap arose and what each price typically includes.

How the decision gets made, and what happens at your consultation

Switching back to Mounjaro from Wegovy is a clinical decision, not a product choice. The prescriber reviewing your consultation will want to understand your weight-loss history on both medicines, any side effects you experienced, your current BMI and health conditions, any changes to your contraception or other medicines (tirzepatide has a specific interaction with oral contraceptives for the first four weeks of treatment and after each dose increase, which semaglutide does not, your prescriber will advise), and your reasons for wanting to switch. NHS England's guidance on weight-management injections is a useful reference for understanding what a thorough clinical review covers.

At nume, the prescriber who reviews your case is a named GPhC-registered Independent Prescriber. Every repeat order is clinically re-reviewed; there are no auto-renewals. If you have been on a previous provider's programme, we ask for evidence of your current treatment before issuing any prescription. That protects you as much as it protects the integrity of the clinical process.

If you moved from Mounjaro to Wegovy and are wondering whether the reverse journey makes sense, our page on whether switching from Mounjaro to Wegovy works offers useful context from the other direction. For a broader look at what private weight-loss treatment involves, our treatment overview sets out the options. Which medicine suits you is a clinical decision our prescribers make with you, the consultation is the right place to have that conversation.